PHA3002_PHR2001 ANS - Cholinergic Workshop
Overview of Cholinergic Pharmacology
This document covers key concepts related to cholinergic pharmacology, focusing on the two major types of receptors: nicotinic and muscarinic, and their respective roles in both the sympathetic and parasympathetic nervous systems.
Acetylcholine (ACh) and Its Role
Functions of Acetylcholine
ACh acts as a neurotransmitter in various parts of the autonomic nervous system (ANS), influencing both the sympathetic and parasympathetic responses.
Parasympathetic System:
ACh is released at nerve terminals, acting on both nicotinic and muscarinic receptors.
The preganglionic fibers release ACh at parasympathetic ganglia, which are located closer to the target organs than those in the sympathetic system, leading to localized effects.
Parasympathetic Nervous System
Characteristics
The parasympathetic nervous system is referred to as 'rest and digest' due to its role in conserving energy and replenishing bodily resources.
Pre-ganglionic fibers originate from cranial nerves and the sacral region of the spinal cord, making connections with a limited number of post-ganglionic fibers, ensuring focused and localized responses.
Cholinergic Receptors
Types of Receptors
Nicotinic Receptors:
Found at the neuromuscular junction and in autonomic ganglia.
Function as ionotropic receptors, which means they form ion channels that open when ACh binds, allowing ions to flow and trigger muscle contractions or neuronal depolarization.
Muscarinic Receptors:
Located in various tissues, including smooth muscle, cardiac muscle, and glands.
Function as metabotropic receptors coupled with G-proteins, leading to slower, longer-lasting effects than nicotinic receptors.
There are five subtypes of muscarinic receptors (M1-M5), each with specific roles throughout the body.
Historical Experimentation
Otto Loewi's Experiment
In 1920, Otto Loewi conducted a groundbreaking experiment that established the principle of chemical transmission in the nervous system through the action of ACh, called "Vagusstoff."
His work demonstrated that stimulation of the vagus nerve in a frog's heart resulted in the release of a fluid that could slow the heart rate in a second frog, proving the chemical nature of neurotransmission.
Pharmacological Interventions
Cholinergic Antagonists and Agonists
Anticholinesterases: Drugs that inhibit the enzyme acetylcholinesterase (AChE), which breaks down ACh, increasing ACh levels at synapses and enhancing cholinergic neurotransmission.
Three classifications by duration include short-acting (e.g., Edrophonium), medium-acting (e.g., Neostigmine), and irreversible long-acting agents (e.g., organophosphates).
Muscarinic Antagonists: Competitive antagonists that block muscarinic receptors, leading to various physiological effects such as increased heart rate and relaxation of smooth muscles.
Examples of Cholinergic Drugs:
Agonists: Bethanechol, Pilocarpine which stimulate action on the muscarinic receptors.
Antagonists: Atropine, Scopolamine used to decrease secretions and manage motion sickness.
Clinical Implications
Myasthenia Gravis
An autoimmune disorder characterized by antibodies that block nicotinic receptors at the neuromuscular junction, leading to severe muscle weakness. Treatment may involve anticholinesterases to enhance neurotransmission at the affected synapses.
Summary of Cholinergic Actions
Muscarinic receptor agonists (stimulators) lead to a range of effects including promoting secretion, decreasing heart rate, and causing smooth muscle contraction.
Antagonists can cause effects like dry mouth, increased heart rate, and cognitive effects on the central nervous system.